Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20


A review and update on orphan drugs for the treatment of noninfectious uveitis.

You C, Sahawneh HF, Ma L, Kubaisi B, Schmidt A, Foster CS.

Clin Ophthalmol. 2017 Jan 31;11:257-265. doi: 10.2147/OPTH.S121734. eCollection 2017. Review.


Extraintestinal Manifestations of Inflammatory Bowel Disease.

Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G.

Inflamm Bowel Dis. 2015 Aug;21(8):1982-92. doi: 10.1097/MIB.0000000000000392. Review.


Update on the therapy of Behçet disease.

Saleh Z, Arayssi T.

Ther Adv Chronic Dis. 2014 May;5(3):112-34. doi: 10.1177/2040622314523062. Review.


Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.

Pasadhika S, Rosenbaum JT.

Biologics. 2014 Feb 15;8:67-81. doi: 10.2147/BTT.S41477. eCollection 2014. Review.


Birdshot uveitis: current and emerging treatment options.

Menezo V, Taylor SR.

Clin Ophthalmol. 2014;8:73-81. doi: 10.2147/OPTH.S54832. Epub 2013 Dec 18. Review.


Ex-vivo tolerogenic F4/80⁺ antigen-presenting cells (APC) induce efferent CD8⁺ regulatory T cell-dependent suppression of experimental autoimmune uveitis.

Hsu SM, Mathew R, Taylor AW, Stein-Streilein J.

Clin Exp Immunol. 2014 Apr;176(1):37-48. doi: 10.1111/cei.12243.


Behcet's disease: systemic and ocular manifestations.

Paovic J, Paovic P, Sredovic V.

Biomed Res Int. 2013;2013:247345. doi: 10.1155/2013/247345. Epub 2013 Oct 3.


Correlation between Ocular Manifestations and Their Complications as Opposed to Visual Acuity and Treatment in Behcet's Disease.

Paovic J, Paovic P, Sredovic V.

Autoimmune Dis. 2013;2013:842673. doi: 10.1155/2013/842673. Epub 2013 Aug 29.


Medical management of uveitis - current trends.

Babu K, Mahendradas P.

Indian J Ophthalmol. 2013 Jun;61(6):277-83. doi: 10.4103/0301-4738.114099. Review.


Infliximab therapy for hepatic and intestinal sarcoidosis.

Te HS, Campbell L, Chohan S.

Gastroenterol Hepatol (N Y). 2007 Jun;3(6):447-52. No abstract available.


Biologic agents in inflammatory eye disease.

Posarelli C, Arapi I, Figus M, Neri P.

J Ophthalmic Vis Res. 2011 Oct;6(4):309-16.


Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients.

Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E, Susini M, Lenzetti I.

Biologics. 2012;6:5-12. doi: 10.2147/BTT.S27343. Epub 2011 Dec 29.


Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis.

Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M.

Graefes Arch Clin Exp Ophthalmol. 2012 May;250(5):713-20. doi: 10.1007/s00417-011-1844-0. Epub 2011 Nov 27.


Emerging role of antioxidants in the protection of uveitis complications.

Yadav UC, Kalariya NM, Ramana KV.

Curr Med Chem. 2011;18(6):931-42. Review.


Barrier dysfunction of the corneal endothelium in response to TNF-alpha: role of p38 MAP kinase.

Shivanna M, Rajashekhar G, Srinivas SP.

Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1575-82. doi: 10.1167/iovs.09-4343. Epub 2009 Sep 24.


Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis.

Callejas-Rubio JL, López-Pérez L, Ortego-Centeno N.

Ther Clin Risk Manag. 2008 Dec;4(6):1305-13.


Adalimumab: a new modality for Behçet's disease?

van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM.

Ann Rheum Dis. 2007 Apr;66(4):565-6. Epub 2006 Nov 23. No abstract available.


TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage.

Vinores SA, Xiao WH, Shen J, Campochiaro PA.

J Neuroimmunol. 2007 Jan;182(1-2):73-9. Epub 2006 Nov 14.


Adalimumab in the therapy of uveitis in childhood.

Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M.

Br J Ophthalmol. 2007 Mar;91(3):319-24. Epub 2006 Oct 11.

Supplemental Content

Support Center